+34 620 10 75 37info@nanbiosis.com

Biomolecules production - Services

Biomolecules production – Services

U29-S02. Modification of oligonucleotides. (Remote) OUTSTANDING

Modification of oligonucleotides

This service is dedicated to the custom synthesis of oligonucleotide conjugates including oligonucleotides carrying lipids, amino acids, peptides or carbohydrates. In addition, they may include other modifications such as phosphorothioate linkages, 2’-O-methyl-RNA, 2’-O-MOE-RNA, 2′-F-RNA, Locked nucleic acids (LNA), modified nucleotides. The oligonucleotides will be prepared in 1 micromol scale. In most cases, the preparation of the conjugates will require the preparation of oligonucleotides carrying reactive groups such as; amino or thiol groups, which will be subjected to a post-synthetic modification. Purification and characterization will include reversed-phase HPLC analysis and mass spectrometry (MALDI-TOF).

Modification of oligonucleotides during and post synthesis to meet user requirements:

  • Conjugation of oligonucleotides with fluorophores (fluoresceine, Cy3, Ct5, etc..) and other types of small molecules such as biotine, lipids.
  • Conjugation to peptides.
  • Phosphorothioate linkages
  • Modified backbones such as locked nucleic acids (LNA), 2’-O-alkyl-RNA, etc..
  • Modified nucleobases: 2-aminopurine, 5-methyl-dC, etc…
  • 5’, 3’-modifications such as 5’-, 3’-amino, 5’-, 3’-thiol, etc..

Customer benefits

The service benefits from the 40-years’ experience of the researchers participating in the service, with hundreds of scientific communications on improving the methodology used for the synthesis of modified oligonucleotides. This includes fatty acid derivatives, amino acids, cell penetrating peptides and carbohydrates not available from other services. In addition, the service can develop customized solutions for molecules not addressed in the bibliography.

Target customer

The primary audience are research groups and companies working on gene therapy and gene inhibition in the early stages of preclinical development.

References

1) “Aptamer-peptide conjugates as a new strategy to modulate human α-thrombin binding affinity”. Aviñó, A. et al. Biochim. Biophys. Acta (General subjects), 1863, 1610-1630 (2019).
2) “Synthesis of oligonucleotides carrying amino-lipid groups at the 3’-end for RNA interference studies”. Grijalvo, S. et al. J. Org. Chem., 75, 6806-6813 (2010).
3) “Synthesis and evaluation of 3’ oleyl-oligonucleotide conjugates as potential cellular uptake enhancers”. Navarro, N. et al. SYNLETT, in press (2024). doi: 10.1055/s-0042-1751528.

Read More

U29-S03. Special nucleotides for oligonucleotide synthesis. (Remote) OUTSTANDING

Special nucleotides for oligonucleotide synthesis

This service is dedicated to the custom synthesis of modified nucleotides such as nucleoside monophosphates or triphosphates as well as special phosphoramidites or functionalized solid supports functionalized with small molecules resistant to ammonia deprotection for the preparation of oligonucleotide conjugates.

Special nucleotides for oligonucleotide synthesis

For those services identified as outstanding, at least 20% of their capacity is open under competitive access. See Annex 1 of ACCESS PROTOCOL (provided by Nanbiosis) for details on % of openness for each service

Customer benefits

The service benefits from the 40-years’ experience of the researchers participating in the service with hundreds of scientific communications on improving the methodology used for the synthesis of modified oligonucleotides. This includes a range of modified nucleotides and terminal modifications not available in other services. In addition, the service can develop customized solutions for molecules not covered in the bibliography.

Target customer

The primary audience are research groups and companies involved in gene therapy, gene silencing and the development of nucleic acid-based diagnostic tools.

References

1) “Oligonucleotides containing 1’-aminomethyl or 1’-mercaptomethyl-2’-deoxy-D-ribofuranoses: Synthesis, purification, characterization and conjugation with fluorophores and lipids”. Martín-Nieves, V. et al. Bioconjugate Chem, 32, 350-366 (2021).
2) “Efficient bioactive oligonucleotide-protein conjugation for cell-targeted cancer therapy”. Aviñó, A. et al. Chemistry Open, 8, 382-387 (2019).
3) “Thioctic acid derivatives as building blocks to incorporate DNA oligonucleotides onto gold nanoparticles”. Pérez-Rentero, S. et al. Molecules, 19, 10495-10523 (2014).

Read More

U29-S01. Synthesis of oligonucleotides and characterization (On-site & Remote). OUTSTANDING

Synthesis of oligonucleotides and characterization

This service is dedicated to the custom synthesis of modified oligonucleotides including phosphorothioate linkages, 2’-O-methyl-RNA, 2’-O-MOE-RNA, 2′-F-RNA, Locked nucleic acids (LNA), modified nucleotides and several others. The oligonucleotides will be prepared on a 1 micromol scale. Purification and characterization will include reversed-phase HPLC analysis and mass spectrometry (MALDI-TOF).

Synthesis of oligonucleotides at various different scales (100 microg to 5 mg) and purification using HPLC and/or desalting.

Customer benefits

The service benefits from the 40-years’ experience of the researchers involved in the service, with hundreds of scientific communications on improving the methodology used for the synthesis of modified oligonucleotides. This expertise includes a range of modified nucleotides and terminal modifications that are not available in other services. In addition, the service can develop customized solutions for molecules not covered in the bibliography.

Target customer

The primary audience are research groups and companies involved in mutagenesis, gene therapy,  gene inhibition, the development of nucleic acid-based diagnostic tools, or the study of nucleic acid structure and nucleic acid-protein interaction.

References

1) “Detection of SARS-CoV-2 virus by Triplex Enhanced Nucleic Acid Detection Assay (TENADA)”, Aviñó, A., et al. Int. J. Mol. Sci., 23, 15258 (2022).
2) “Properties of parallel tetramolecular G-quadruplex carrying N-acetylgalactosamine as potential enhancers for oligonucleotide delivery to hepatocytes”. Clua, A. et al. Molecules, 27, 3944, (2022).
3) “Chemical modifications in nucleic acids for therapeutic and diagnostic applications”. Fàbrega, C., Aviñó, A., Eritja, R. The Chemical Record, 22, e202100270 (2022).

Read More

U28-S07. Transmission Electron Microscopy (TEM)

Transmission Electron Microscopy (TEM)

The Electron Microscopy Service offers access to transmission electron microscopy (TEM), cryo-TEM and electron tomography, high resolution scanning electron microscopy (SEM), and environmental SEM. A special emphasis has been made on high-end sample preparation techniques through cryo-immobilization. All the equipment has been configured to provide its best for biological and nanomedicine applications.

Customer benefits

We have SOPs and ISO9001 certification. We also have specialist technicians for the use of the equipment.

This service is essential to:

  • Cellular characterization: cell structures and ultrastructures visualization and its relationship to function are the most important contributions of EM to cell biology.
  • Tissue characterization: electron microscopy has a role in the characterization of interactions between cells and with other components inside tissues.
  • Biomaterials characterization: electron microscopy plays a double role in biomaterial characterization On one hand, it provides structural and compositional information on the materials engineered to be used inside biological systems, favouring its development On the other hand, it allows us to visualize their interactions Functionalized polymeric and metallic nanoparticles for drug delivery, dental implants, bone plates and cements, and artificial tissues are among the biomaterials that can benefit from the information provided by EM.
  • Macromolecular complexes characterization: structural biology can benefit from electron microscopy to determine 3D structures of macromolecular complexes.
  • Negative staining is also a very valuable tool for 2D-3D characterization.

Target customer

Any company or research group interested in:

  • Transmission electron microscopy of resin-embedded and non-embedded samples.
  • Cryo-fixation of samples at high pressure (High-Pressure Freezing).
  • Resin embedding of samples at room temperature (conventional) or low temperature (freeze-substitution) for ultramicrotomy.
  • Ultramicrotomy of resin-embedded sections (semithin and ultrathin sections).
  • Data and image processing.
  • Technical advice for users regarding the selection of protocols and procedures for experiments involving electron microscopy.

References

  1. Gómez-González E, González-Mancebo D, Núñez NO, Caro C, García-Martín ML, Becerro AI, Ocaña M. Lanthanide vanadate-based trimodal probes for near-infrared luminescent bioimaging, high-field magnetic resonance imaging, and X-ray computed tomography. J Colloid Interface Sci. 2023 Sep 15;646:721-731. doi: 10.1016/j.jcis.2023.05.078. Epub 2023 May 18. PMID: 37229990.
  2. Caro C, Guzzi C, Moral-Sánchez I, Urbano-Gámez JD, Beltrán AM, García-Martín ML. Smart Design of ZnFe and ZnFe@Fe Nanoparticles for MRI-Tracked Magnetic Hyperthermia Therapy: Challenging Classical Theories of Nanoparticles Growth and Nanomagnetism. Adv Healthc Mater. 2024 Feb 2:e2304044. doi: 10.1002/adhm.202304044. Epub ahead of print. PMID: 38303644.

Read More

U3-S04. Peptide libraries (Remote) OUTSTANDING

Peptide libraries.

Read More

U3-S03. Special amino acids for peptidomimetics synthesis (Remote) OUTSTANDING

Special amino acids for peptidomimetics synthesis (Remote) OUTSTANDING

– Synthesis of N-alkyl amino acids and other special amino acids
– Synthesis of peptoids (N-alkylglycine oligomers).
– Synthesis of β-peptide, γ- peptides, β,γ-peptides and α,β-peptides
– Synthesis of peptidomimetics
– Synthesis of hybrid-heterocycle- peptides

Customer benefits

  • Extensive experience in the synthesis of peptide oligomers from non-natural amino acids such as β-peptides, γ-peptides, β,γ-peptides and α,β-peptides.
  • Experience with peptides and peptide mimetics in solid phase and in solution.
  • Development of various strategies for large-scale production (hundreds of mg) of peptidomimetics.

Target customer

  • Research groups (drug delivery, molecular biology, pharmacology, nanotechnology, biotechnology)
  • Companies (biotech and pharma companies).

References

  • Hybrid cyclobutane/proline-containing peptidomimetics: the conformational constraint influences their cell-penetration ability. Illa, Ona ; Ospina, Jimena; Sanchez-Aparicio, Jose-Emilio; Pulido, Ximena ; Abengozar, Maria Angeles; Gaztelumendi, Nerea; Carbajo, Daniel; Nogues, Carme; Rivas, Luis ; Marechal, Jean-Didier; Royo, Miriam ; Ortuño, Rosa M. International Journal of Molecular Sciences (2021), 22, 5092.
  • Chiral cyclobutane-containing cell-penetrating peptides as selective vectors for anti-Leishmania drug delivery systems. Illa, Ona ; Olivares, Jose-Antonio; Gaztelumendi, Nerea; Martinez-Castro, Laura; Ospina, Jimena; Abengozar, Maria-Angeles; Sciortino, Giuseppe ; Marechal, Jean-Didier; Nogues, Carme; Royo, Miriam; Rivas, Luis; Ortuno, Rosa M. International Journal of Molecular Sciences (2020), 21, 7502.
  • A solid-phase combinatorial approach for indoloquinolizidine-peptides with high affinity at D1 and D2 dopamine receptors. Molero, Anabel; Vendrell, Marc; Bonaventura, Jordi; Zachmann, Julian; Lopez, Laura; Pardo, Leonardo; Lluis, Carme; Cortes, Antoni; Albericio, Fernando; Casado, Vicent; Royo, Miriam. European Journal of Medicinal Chemistry (2015), 97, 173-180.
  • Efficient γ-amino-proline-derived cell penetrating peptide-superparamagnetic iron oxide nanoparticle conjugates via aniline-catalyzed oxime chemistry as bimodal imaging nanoagents. Cavalli, Silvia; Carbajo, Daniel; Acosta, Milena; Lope-Piedrafita, Silvia; Candiota, Ana Paula; Arus, Carles; Royo, Miriam; Albericio, Fernando. Chemical Communications (2012), 48, 5322-5324.

Read More

U2-S08. Inmunochemical methods development

Inmunochemical methods development

The service offers custom tailored immunoassay development. It involves designing and optimizing assays for detecting specific analytes (such as proteins, antibodies, or other biomolecules) in biological samples. The service includes identifying necessary reagents, establishing assay parameters, and validating the assay’s performance.

Customer benefits

  • Tailored Solutions: By utilizing our custom tailored immunoassay development service, customers gain access to highly specialized expertise and resources, resulting in the creation of assays optimized for their unique requirements.
  • Enhanced Sensitivity: The service ensures optimal sensitivity, allowing for the detection of analytes at low concentrations.
  • Time and Cost Savings: Outsourcing immunoassay development to experts saves time and resources compared to in-house development.
  • Quality Assurance: Rigorous validation ensures reliable results, enhancing confidence in research outcomes.

Target customer

  • Research Institutions: Universities, research centers, and laboratories engaged in biomedical research.
  • Biotech Companies: Organizations involved in drug discovery, diagnostics, and therapeutic development.
  • Pharmaceutical Companies: Those working on antibody-based therapies or vaccines.
  • Healthcare Providers: Hospitals and clinics conducting specialized research.
  • Food & Environmental Quality Control Companies: Entities involved in:
    • Food Contaminant Detection: Developing antibody-based
      tests for identifying foodborne pathogens and toxins.
    • Environmental Contaminant Detection: Creating antibody-based assays for detecting environmental pollutants in air, water, and soil.

Additional information

Selected references:

  • G. Colom, A. Hernández-Albors, J. Barallat, A. Galan, A. Bayes-Genis, J.-P. Salvador, M.-P. Marco. A multiplexed immunochemical microarray for the determination of cardiovascular disease biomarkers. Microchim. Acta, 191, 54, 2023.
  • C. Adrover-Jaume, A. Clemente, B. Rodríguez-Urretavizcaya, L. Vilaplana, M.-Pilar Marco, E. Rojo-Molinero, A. Oliver, R. de la Rica. A paper biosensor for overcoming matrix effects interfering with the detection of sputum pyocyanin with competitive immunoassays. Microchim acta, 190, 441, 2023.
  • E. Montagut, J. Raya, M.-T. Martín Gómez, L. Vilaplana, B. Rodríguez- Urretavizcaya, M.-P. Marco. An Immunochemical Approach to detect the Quorum Sensing-Regulated Virulence Factor 2-Heptyl-4- Quinoline N-Oxide (HQNO) produced by Pseudomonas aeruginosa Clinical Isolates. Microbiol. Spect., 10(4), 1-12, 2022.
  • E. Montagut, G. Acosta, F. Albericio, M. Royo, G. Godoy-Tena, A. Lacoma, C. Prat, J.-P. Salvador, M.-P. Marco. Direct Quantitative Immunochemical Analysis of the Autoinducer Peptide IV (AIP-IV) for Diagnosing and Stratifying Staphylococcus aureus infections. ACS Infect. Dis., 8(3), 645-656, 2022.
  • B. Rodriguez-Urretavizcaya, N. Pascual, C. Pastells, M. T. Martin-Gomez, Ll. Vilaplana, M.-P. Marco. Diagnostic and Stratification of Pseudomonas aeruginosa Infected Patients by Immunochemical Quantitative Determination of Pyocyanin from Clinical Bacterial Isolates. Frontiers in Cell. Infect. Microbiol., 11, 786929, 2021. DOI: 10.3389/fcimb.2021.786929
Read More

U2-S07. Antibody purification

Antibody purification

Antibody purification involves the selective enrichment or specific isolation of antibodies from various sources, such as serum (for polyclonal antibodies), or cell culture supernatant (for monoclonal antibodies).

The main methods used for antibody purification are:

  • Physicochemical Fractionation: This method includes differential precipitation, size-exclusion, or ion exchange chromatography, based on size, charge, or other shared chemical characteristics It separates proteins that includes the immunoglobulins (antibodies) based on size, charge, or other shared chemical characteristics
  • Class-Specific Affinity: In this approach, specific antibody classes (e.g., IgG) are bound to solid phases using immobilized biological ligands (such as proteins A or G). This method purifies all antibodies of the target class without considering antigen specificity.
  • Antigen-Specific Affinity: Here, only antibodies in a sample that bind to a particular antigen are purified. Affinity chromatography is performed using a column packed with immobilized antigen (the same antigen used for immunization). Only antibodies that bind to the antigen are isolated. This method provides a higher yield of antigen-specific antibodies than Protein A/G affinity chromatography, though the total amount of recovered antibodies is lower.

Customer benefits

  • High Purity: Antibody purification ensures that the isolated antibodies are of high purity, minimizing contamination by other proteins.
  • Specificity: By using antigen-specific affinity purification, researchers obtain antibodies that specifically recognize their target antigen.
  • Consistent Results: Purified antibodies lead to more consistent and reliable experimental results.
  • Diagnostic and Therapeutic Applications: Purified antibodies are essential for diagnostic assays, therapeutic development, and research applications.
  • Quality: We operate under ISO 9001 quality standards, ensuring consistent, reliable antibody production.

Target customer

  • Research Institutions: Universities, research centers, and laboratories engaged in biomedical research.
  • Biotech Companies: Organizations involved in drug discovery, diagnostics, and therapeutic development.
  • Pharmaceutical Companies: Those working on antibody-based therapies or vaccines.
  • Healthcare Providers: Hospitals and clinics conducting specialized research.
  • Food & Environmental Quality Control Companies: Entities involved in:
    • Food Contaminant Detection: Developing antibody-based tests for identifying foodborne pathogens and toxins.
    • Environmental Contaminant Detection: Creating antibody-based assays for detecting environmental pollutants in air, water, and soil.

Additional information

Selected references:

  • Giovanna Roncador; Pablo Engel; Lorena Maestre; et al; Alison H.Banham., Nuria Pascual 2016. The European antibody network’s practical guide to finding and validating suitable antibodies for research. mAbs. Taylor & Francis Online. 8-1, pp.27-36.
  • B. Rodriguez-Urretavizcaya, N. Pascual, C. Pastells, M. T. Martin-Gomez, Ll. Vilaplana, M.-P. Marco. Diagnostic and Stratification of Pseudomonas aeruginosa Infected Patients by Immunochemical Quantitative Determination of Pyocyanin from Clinical Bacterial Isolates. Frontiers in Cell. Infect. Microbiol., 11, 786929, 2021. DOI: 10.3389/fcimb.2021.786929
Read More

U2-S06. In vitro antibody production

In vitro antibody production

We perform the production of monoclonal antibodies in vitro.
Hybridoma cells are first expanded in culture flask or high density culture devices (for larger amounts of antibody) to get the optimal cell density needed for the production.
The classical medium of production includes fetal calf serum (ultralow IgG, FCS) but our expertise allows us to provide a completely customized service according to your needs, without using FCS.
Supernatant containing the monoclonal antibodies is then periodically collected until the expected quantity of antibodies is obtained.

Depending on the nature of the sample, the expected antibody concentrations are for :­

  • Culture in flask: from 5 to 20 µg antibody/mL supernatant
  • ­ Culture in high density device : up to 1 mg antibody/mL supernatant

Customer benefits

  • Customization: The service can be tailored to meet the specific needs of each customer, allowing for personalized antibody production without using fetal calf serum (FCS).
  • Scalability: The service can accommodate both flask cultures and high-density devices, providing flexibility for different antibody quantities.
  • ISO 9001 Certification: We operate under ISO 9001:2015 quality standards, ensuring consistent and reliable antibody production.

Target customer

  • Research Institutions: Universities, research centers, and laboratories engaged in biomedical research.
  • Biotech Companies: Organizations involved in drug discovery, diagnostics, and therapeutic development.
  • Pharmaceutical Companies: Those working on antibody-based therapies or vaccines.
  • Healthcare Providers: Hospitals and clinics conducting specialized research.
  • Food & Environmental Quality Control Companies: Entities involved in:
    • Food Contaminant Detection: Developing antibody-based tests for identifying foodborne pathogens and toxins.
    • Environmental Contaminant Detection: Creating antibody-based assays for detecting environmental pollutants in air, water, and soil.

Additional information

Selected references:

  • Giovanna Roncador; Pablo Engel; Lorena Maestre; et al; Alison H.Banham., Nuria Pascual 2016. The European antibody network’s practical guide to finding and validating suitable antibodies for research. mAbs. Taylor & Francis Online. 8-1, pp.27-36
  • Rodriguez-Urretavizcaya, N. Pascual, C. Pastells, M. T. Martin-Gomez, Ll. Vilaplana, M.-P. Marco. Diagnostic and Stratification of Pseudomonas aeruginosa Infected Patients by Immunochemical Quantitative Determination of Pyocyanin from Clinical Bacterial Isolates. Frontiers in Cell. Infect. Microbiol., 11, 786929, 2021. DOI: 10.3389/fcimb.2021.786929

Read More

U2-S05. Monoclonal Antibody development

Monoclonal Antibody development

To develop customized monoclonal antibodies, we adapt our protocols at each critical stage of antibody production. This includes designing the antigen, immunization protocol, and screening design of hybridoma cell supernatants. The initial step involves immunizing mice or rats with a specific antigen. We can develop monoclonal antibodies against various antigen types, such as proteins, peptides, small molecules, or cells. The immunization process typically spans 10-12 weeks. The animal with the most robust immune response undergoes a final immunization to stimulate antibody-producing cells. Spleen cells are isolated and fused with immortal myeloma cell lines to create hybridoma cells. The chosen hybridoma clones are then subcloned to ensure cell stability and maintain their monoclonal characteristics. Finally, the isolated cells are expanded and cryopreserved.

Customer benefits

  • Versatility: Monoclonal antibodies can be used in diagnostics, therapeutics, and research.
  • Customization: Protocols can be adapted to meet specific needs
  • Quality Assurance: Our processes adhere to the ISO 9001 quality requirements.

Target customer

  • Organizations involved in research and development, pharmaceutical companies, academic institutions, and diagnostic laboratories benefit from monoclonal antibody development.
  • Researchers studying diseases, drug targets, and immune responses rely on mAbs for their work.

Additional information

Monoclonal antibody development workflow

Selected references:

  • Giovanna Roncador; Pablo Engel; Lorena Maestre; et al; Alison H.Banham., Nuria Pascual 2016. The European antibody network’s practical guide to finding and validating suitable antibodies for research. mAbs. Taylor & Francis Online. 8-1, pp.27-36
  • Rodriguez-Urretavizcaya, N. Pascual, C. Pastells, M. T. Martin-Gomez, Ll. Vilaplana, M.-P. Marco. Diagnostic and Stratification of Pseudomonas aeruginosa Infected Patients by Immunochemical Quantitative Determination of Pyocyanin from Clinical Bacterial Isolates. Frontiers in Cell. Infect. Microbiol., 11, 786929, 2021. DOI: 10.3389/fcimb.2021.786929
Read More